Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)-Reference-Cited by-同舟云学术

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)

Published:2019-10 Issue:4 Volume:76 Page:437-440
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

De Bruijn Roderick Emile,Mulders Peter,Jewett Michael A.,Wagstaff John,Van Thienen Johan V.,Blank Christian U.,Van Velthoven Roland,Wood Lori,van Melick Harm E.,Aarts Maureen J.,Lattouf Jean B.,Powles Thomas,De Jong Igle J.,Rottey Sylvie,Tombal Betrand,Marreaud Sandrine,Collette Sandra,Collette Laurence,Haanen John B.,Bex Axel

Funder

European Organisation for Research and Treatment of Cancer

Publisher

Elsevier BV

Subject

Urology

Reference10 articles.

1. Sunitinib alone or after nephrectomy in metastatic renal cell carcinoma;Méjean;N Engl J Med,2018

2. Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2018.5543.

3. Updated European Association of urology guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma;Bex;Eur Urol,2018

4. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma;Margulis;J Urol,2008

5. Surgical resection of renal cell carcinoma after targeted therapy;Thomas;J Urol,2009

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytoreductive nephrectomy in metastatic renal cell carcinoma;Cochrane Database of Systematic Reviews;2024-06-07

2. The Role of Surgery in Metastatic Renal Cell Carcinoma in 2024;Clinical Medicine Insights: Oncology;2024-01

3. Comparison of upfront versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving systemic therapy: A systematic review and meta-analysis;International Journal of Surgery;2023-07-17

4. CEACAM1 Is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Clear Cell Renal Cell Carcinoma;Disease Markers;2023-01-18

5. The Role of Immunotherapy in Renal Cell Carcinoma;Handbook of Cancer and Immunology;2023